Clinical development of phosphatidylinositol 3-kinase inhibitors for cancer treatment
<p>Abstract</p> <p>The phosphatidylinositol 3-kinase (PI3K) pathway is commonly deregulated in cancer. In recent years, the results of the first phase I clinical trials with PI3K inhibitors have become available. In comparison to other targeted agents such v-raf murine sarcoma vira...
Main Authors: | Brana Irene, Siu Lillian L |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2012-12-01
|
Series: | BMC Medicine |
Subjects: | |
Online Access: | http://www.biomedcentral.com/1741-7015/10/161 |
Similar Items
-
Class I phosphatidylinositol 3-kinase inhibitors for cancer therapy
by: Wennan Zhao, et al.
Published: (2017-01-01) -
Implication d'isoformes distinctes de la phosphatidylinositol 3-kinase dans la survie entérocytaire humaine selon l'état de différenciation
by: Noël, Dominique
Published: (2011) -
PI3K inhibitors as new cancer therapeutics: implications for clinical trial design
by: Massacesi C, et al.
Published: (2016-01-01) -
The role of phosphoinositide 3-kinase subunits in chronic thyroiditis
by: Wojciechowska-Durczynska Katarzyna, et al.
Published: (2012-12-01) -
Structural Determinants of Isoform Selectivity in PI3K Inhibitors
by: Michelle S. Miller, et al.
Published: (2019-02-01)